From: zerohedge OpenAI Seeks $90 Billion Valuation In Potential Sale Of Existing Shares | ZeroHedge OpenAI has been in discussions with investors about a possible share sale which would value the AI startup behind ChatGPT at between $80 and $90 billion, nearly triple what it went for in an April share sale. The startup, which[…]
From: zerohedge Musk’s Brain Implant Startup Receives FDA Approval For Human Tests | ZeroHedge Elon Musk’s brain-implant startup received approval from the Food and Drug Administration to conduct clinical trials of its experimental device in humans. “We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study!” Neuralink[…]
From Crunchbase News: Last month saw some big deals roll in, including the second-biggest of the year to date. However, the month significantly slowed — especially in terms of monster deals — as it wore on. That could well be due to Silicon Valley Bank’s collapse having at least some short-term effects on fundraising. That will[…]
From Bloomberg: SpaceX headquarters in Hawthorne, California.Photographer: Alisha Jucevic/Bloomberg By Gillian Tan, Edward Ludlow, and Giles Turner November 15, 2022 at 12:30 PM EST Elon Musk’s SpaceX is in talks to raise a funding round that values the rocket-launch and satellite company at more than $150 billion, people familiar with the matter said. The transaction being discussed[…]
Parker Conrad — May 11, 2022 Rippling has raised $250M in a round co-led by Bedrock and Kleiner Perkins, with participation from existing investors Y Combinator, Sequoia Capital, and more. The round values the company at $11.25 billion. I’m grateful for these investors’ conviction in Rippling, for the employees that have gotten us to this point,[…]
By Niloofer Shaikh, HilleVax (HLVX) has priced its upsized initial public offering of 11.765M shares of common stock at $17.00 per share, for gross proceeds of approximately $200M. The offering was upsized from $10.3M shares to 11.765M shares and priced within the estimated range of $16 and $18 per share. The shares are expected to begin trading on[…]
By Renaissance Capital, Bellevue Life Sciences Acquisition, a blank check company backed by Bellevue Capital Management targeting the biotech sector, filed on Friday with the SEC to raise up to $60 million in an initial public offering. The Bellevue, WA-based company plans to raise $60 million by offering 6 million units at $10. Each unit[…]
By Renaissance Capital, Bausch + Lomb, a leading supplier of contact lenses and eyecare products, announced terms for its IPO on Thursday. The company plans to dual list on the Toronto Stock Exchange. The Vaughan, Canada-based company plans to raise $788 million by offering 35 million shares (100% secondary) at a price range of $21 to[…]
By Val Kennedy, Novovirus vaccine developer HilleVax (HLVX) has upsized its initial public offering to $175M from $100M. The biotech company said in an amended filing on Monday that it now plans to offer 10.3M shares priced between $16 and $18 per share. If priced at the midpoint, the company would raise approximately $175M. In a filing[…]
By Val Kennedy, BioAffinity Technologies (BIAF), which is developing a test to better detect lung cancer in its earliest stages, has filed for a $19M initial public offering. The Texas-based diagnostics maker didn’t specify the number of shares to be offered and their pricing, but indicated that it hoped to raise up to $19M through[…]